The present invention relates to the use of NAD(P)H oxidase inhibitors to increase
cellular uptake of glucose and in the treatment and/or prevention of diseases caused
by insulin resistance or diseases related thereto, such as type II diabetes. Specifically,
the invention relates to a method for identifying an agent useful for the treatment
or prophylaxis of a medical condition associated with elevated levels of blood
glucose, the method comprising (i) contacting a candidate agent with a mammalian
NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate
agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.
